Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

LATA HIV Injectable Trial Results

Analysis based on 13 articles · First reported Sep 17, 2026 · Last updated Sep 22, 2026

Sentiment
15
Attention
2
Articles
13
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The results could support broader uptake of long-acting injectable HIV regimens, a positive long-term signal for the pharmaceutical companies supplying cabotegravir and rilpivirine, though near-term revenue impact is limited by cost and access barriers in low-income settings. Overall market impact is modest, as the trial is a clinical and public-health development rather than a commercial or macroeconomic event.

pharmaceuticals healthcare

A UCL-led clinical trial in Africa, the LATA (Long-Acting Treatment in Adolescents) trial, found that long-acting injectable antiretroviral therapy given every eight weeks was more effective than daily tablets at maintaining viral suppression in adolescents living with HIV. The trial enrolled 476 adolescents aged 12 to 19 across five clinics in Kenya, South Africa, Uganda and Zimbabwe, randomly assigning them to daily tablets or the injectable combination of cabotegravir and rilpivirine. After 96 weeks, only 2 participants (1%) on injectables experienced confirmed viral rebound versus 15 (6%) on daily tablets, and 94% of the injectable group said the eight-weekly injections were much easier than daily medication. Results were published in The Lancet. Researchers, including chief investigator Professor Sarah Pett and Dr Mutsa Bwakura-Dangarembizi, called for wider availability of injectables in Africa, where nine out of ten adolescents with HIV live but the treatment is largely unavailable outside a few clinics. Challenges cited include higher cost due to patents, refrigeration requirements for rilpivirine, and the need for skilled nursing staff. The World Health Organization currently recommends injectables only as an alternative option for adults and adolescents on daily tablets who are successfully suppressing the virus and do not have active hepatitis B; this stance may be strengthened by the findings. The trial was funded by the European Union through EDCTP-2 and Johnson & Johnson Innovative Medicines, which provided rilpivirine, while ViiV Healthcare provided cabotegravir. UCL was the sponsor, with collaboration from institutions including the London School of Hygiene and Tropical Medicine, Radboud University Medical Center, University of York, Baylor College of Medicine, Moi University and University of Zimbabwe.

35 World Health Organization recommended injectables
30 Sarah Pett called for access
25 Deborah Ford warned of inequalities
25 Mutsa Bwakura-Dangarembizi called for availability
stock
Johnson & Johnson Innovative Medicines funded the trial and provided injectable rilpivirine, potentially benefiting from wider adoption of the regimen.
Importance 55.0 Sentiment 10.0
priv
ViiV Healthcare provided injectable cabotegravir for the trial, and positive results could support broader use of its product.
Importance 55.0 Sentiment 10.0
ngo
The WHO currently recommends injectables only as an alternative option; the trial results may lead it to strengthen that guidance.
Importance 45.0 Sentiment 5.0
alliance
The EU funded the trial through EDCTP-2, supporting HIV treatment research in Africa.
Importance 40.0 Sentiment 5.0
cnt
Kenya hosted one of the five trial clinics and stands to benefit from improved adolescent HIV treatment access.
Importance 30.0 Sentiment 5.0
cnt
South Africa hosted trial sites and has a large adolescent HIV population that could benefit from injectable therapy.
Importance 30.0 Sentiment 5.0
cnt
Uganda hosted two trial sites and could gain access to long-acting injectables if availability expands.
Importance 30.0 Sentiment 5.0
cnt
Zimbabwe hosted a trial site in Harare, whose principal investigator highlighted the lack of injectable availability in Africa.
Importance 30.0 Sentiment 5.0
World Health Organization operator ↔ Uganda The World Health Organization operates a country office in Uganda, collaborating with the national government to manage
European Union related ↔ Kenya
European Union related ↔ Uganda
European Union related ↔ Zimbabwe
Kenya related ↔ South Africa
Kenya related ↔ Uganda
Kenya related ↔ Zimbabwe
South Africa related ↔ Uganda
South Africa related ↔ Zimbabwe
Uganda related ↔ Zimbabwe
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.